arrow
V

Vincent Hautefeuille

amiens university hospital
H指数:24
被引数:2,147

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-Line Fluoropyrimidine- versus Gemcitabine-Based Chemotherapy for Metastatic Recurrence After Resection of Ampullary Adenocarcinoma: a Real-World Analysis of the FFCD-AC Cohort

壶腹腺癌切除术后转移性复发的氟嘧啶类与吉西他滨为基础的化疗比较:FFCD-AC队列的真实世界分析

2026-10-090
OAAI
Is pembrolizumab as safe and efficient as neoadjuvant treatment in localized dMMR/MSI esophagogastric cancers? Results from the IMHOTEP phase II study

帕博利珠单抗作为局部dMMR/MSI食管胃癌的新辅助治疗是否安全有效?——IMHOTEP II期研究的结果

2026-09-090
OAAI
Interpretable AIto predict anal cancer local failure at 3 years with the FFCD Anabase prospective multicentric cohort

可解释AI预测FFCD Anabase前瞻性多中心队列中3年肛门癌局部复发

2026-08-010
PRE
Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort)
2026-07-280
OA
Efficacy of targeted therapies for metastatic small bowel adenocarcinoma treatment: a retrospective study by AGEO

靶向疗法治疗转移性小肠腺癌的疗效:AGEO进行的一项回顾性研究

2026-03-280
PRE
Management of biliary tract cancers in elderly patients: a French multicenter retrospective study (PRONOBIL-ACABi)

老年患者胆道肿瘤的管理:一项法国多中心回顾性研究(PRONOBIL-ACABi)

2025-10-030
OA
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

Nal-IRI/LV5-FU 与紫杉醇作为转移性食管鳞状细胞癌患者二线治疗的比较(PRODIGE 62-FFCD 1701-OESIRI)

2025-08-220
OAAI
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study

微卫星不稳定/错配修复缺陷型胆道癌中免疫检查点抑制剂的实时世界疗效:一项AGEO研究

2025-07-300
PRE
Salvage abdominoperineal resection for anal squamous cell carcinoma after radiotherapy or chemoradiotherapy: analysis of the French prospective cohort FFCD-ANABASE

经放疗或放化疗后肛管鳞状细胞癌的挽救性腹会阴联合切除术:法国前瞻性队列FFCD-ANABASE分析

2025-07-280
PRE
Rectal and Rectosigmoid Endoscopy to Assess Endoscopic and Histological Remission in Ulcerative Colitis: A Prospective Study

直肠和直肠乙状结肠内镜检查评估溃疡性结肠炎的内镜及组织学缓解:一项前瞻性研究

2025-05-240
PRE
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)

基于贝伐珠单抗的化疗,根据贝伐珠单抗药代动力学适应性调整,用于不可切除性转移性结直肠癌患者的一线治疗:一项双盲、多中心、随机III期临床试验研究(PHARBEVACOL试验)

2025-05-010
OAAI
Response to systemic treatments and survival of fibrolamellar carcinomas: An AGEO-SFCE French multicenter retrospective cohort

对纤维层状癌的全身性治疗反应与生存:一项法国AGEO-SFCE多中心回顾性队列研究

2025-05-010
OAAI
Real-life data on biliary tract cancers in France: The nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort
2025-01-011
OAAI
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study

直肠腺癌伴同步转移患者的诱导三联化疗:一项AGEO-FFCD研究

2025-01-010
OAAI
Relative dose intensity of first-line triplet chemotherapy in metastatic colorectal cancer
2025-01-010
OAAI
Ampullary tumors: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, ACHBT, AFC, SFRO, RENAPE, SNFCP, AFEF, SFP, SFR)
2024-09-011
OAAI
A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability

一项多中心研究评估免疫检查点抑制剂在具有微卫星不稳定性的晚期非结直肠消化道癌中的疗效

2024-05-013
OA
Management of biliary tract cancers in early-onset patients: A nested multicenter retrospective study of the ACABI GERCOR PRONOBIL cohort

早发患者胆道癌的管理: ACABI GERCOR PRONOBIL队列的巢式多中心回顾性研究

2024-04-081
OAAI
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study
2023-12-153
PRE